Understanding melanoma signaling networks as the basis for molecular targeted therapy

117Citations
Citations of this article
107Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Despite years of research, there has been little improvement in survival for patients with disseminated melanoma. Recent work has identified mutations in BRAF and NRAS, leading to constitutive mitogen-activated protein kinase (MAPK) pathway as well as constitutive activity in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway, as being critical events in melanoma growth and progression. In the current review, we discuss how these complex mutational and signaling profiles can be understood using a network biology approach, and suggest how an understanding of the key signaling nodes involved in progression and survival will lead to improvements in melanoma therapy. © 2010 The Society for Investigative Dermatology.

Cite

CITATION STYLE

APA

Smalley, K. S. M. (2010). Understanding melanoma signaling networks as the basis for molecular targeted therapy. Journal of Investigative Dermatology, 130(1), 28–37. https://doi.org/10.1038/jid.2009.177

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free